Update on adult attention-deficit/hyperactivity disorder

Current Neurology and Neuroscience Reports

Volumn 8, Issue 6, 2008, Pages 484-489

  Hammerness, Paul ^a   Surman, Craig ^a   Miller, Katherine ^a  

^a Clinical and Research Program in Pediatric Psychopharmacology MGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; CENTRAL STIMULANT AGENT;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; COMORBIDITY; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CLINICAL TRIALS AS TOPIC; COMORBIDITY; FEMALE; HUMANS; MALE;

EID: 58149195375     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-008-0077-z     Document Type: Article

References (40)

1. Fayyad J, de Graaf R, Kessler R, et al.: Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007, 190:402-409. This article is notable for its presentation of current prevalence rates for adult ADHD. (Pubitemid 46706952)
2. Kessler RC, Adler L, Barkley R, et al.: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006, 163:716-723. First-of-its-kind report on the prevalence of adult ADHD. (Pubitemid 44464584)
3. Birnbaum HG, Kessler RC, Lowe SW, et al.: Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005, 21:195-206.
4. Kessler RC, Lane M, Stang PE, et al.: The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm. Psychol Med 2008, 21:1-11.
5. de Graaf R, Kessler RC, Fayyad J, et al.: The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med 2008 May 27 (Epub ahead of print).
6. Kessler RC, Adler LA, Ames M, et al.: The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 2005, 35:245-256. (Pubitemid 40259916)
7. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
8. Kessler RC, Adler LA, Gruber MJ, et al.: Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) screener in a representative sample of health plan members. Int J Methods Psychiatr Res 2007, 16:52-65. (Pubitemid 46930456)
9. Yeh CB, Gau SS, Kessler RC, et al.: Psychometric properties of the Chinese version of the adult ADHD Self-Report Scale. Int J Methods Psychiatr Res 2008, 17:45-55.
10. Reinhardt MC, Benetti L, Victor MM, et al.: Is age-at-onset criterion relevant for the response to methylphenidate in attention-deficit/hyperactivity disorder? J Clin Psychiatry 2007, 68:1109-1116. (Pubitemid 47340334)
11. Biederman J, Mick E, Spencer T, et al.: An open-label trial of OROS methylphenidate in adults with late-onset ADHD. CNS Spectr 2006, 11:390-396. (Pubitemid 43727139)
12. Pliszka S, AACAP Work Group on Quality Issues: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007, 46:894-921. The current pediatric guidelines for ADHD.
13. Wilens TE, Rostain AL: Pharmacologic management with methylphenidate in adults with attention-deficit/hyperactivity disorder: an analysis of safety, efficacy, and dosing. Presented at the 2007 annual meeting of the American Psychiatric Association. San Diego; May 2007.
14. Biederman, J, Boellner SW, Childress A, et al.: Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007, 62:970-976. (Pubitemid 47562371)
15. Biederman J, Mick E, Surman C, et al.: A randomized, placebo-controlled trial of OROS-methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006, 59:829-835.
16. Medori R, Ramos-Quiroga JA, Casas M, et al.: A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008, 63:981-989.
17. Weisler RH, Biederman J, Spencer TJ, et al.: Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006, 11:625-639. (Pubitemid 44253518)
18. Wilens T: Drug therapy for adults with attention-deficit hyperactivity disorder. Drugs 2003, 63:2395-2411. (Pubitemid 37392906)
19. Faraone SV, Spencer T, Aleardi M, et al.: Meta-analysis of the efficacy of methylphenidate for treating adult attention deficit hyperactivity disorder. J Clin Psychopharmacol 2004, 54:24-29. (Pubitemid 38134162)
20. Spencer TJ, Adler LA, McGough JJ, et al.: Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2007, 61:1380-1387. (Pubitemid 46855767)
21. Adler L, Dietrich A, Reimherr FW, et al.: Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry 2006, 18:107-113. (Pubitemid 43879898)
22. Michelson D, Adler LA, Spencer T, et al.: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003, 53:112-120. (Pubitemid 36126473)
23. Adler LA, Spencer TJ, Milton DR, et al.: Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/ hyperactivity disorder: an interim analysis. J Clin Psychiatry 2005, 66:294-299. (Pubitemid 40476751)
24. Adler LA, Spencer TJ, Williams DW, et al.: Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 2008 April 30 (Epub ahead of print). This study is notable because the duration of treatment is longer than that reported in many other studies.
25. Adler LA, Goodman DW, Kollins SH, et al.: Efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Presented at the 2008 annual meeting of the American Psychiatric Association. Washington, DC; May 2008.
26. Olfson M, Marcus SM, Zhang HF, et al.: Adult ADHD and stimulant dosing in the community setting. Presented at the 2007 annual meeting of the American Psychiatric Association. San Diego; May 2007.
27. Faraone S: Comparing the efficacy of medications for ADHD using meta-analysis. Presented at the 2006 annual meeting of the American Psychiatric Association. Toronto; May 2006.
28. Adler LA, Morrill M, Reingold B: d-Methylphenidate augmentation of extended-release stimulant therapy in ADHD. Presented at the 2006 annual meeting of the American Psychiatric Association. Toronto; May 2006.
29. Robison RJ, Reimherr FW, Marchant BK, et al.: Gender differences in 2 clinical trials of adults with attention-defi - cit/hyperactivity disorder: a retrospective data analysis. J Clin Psychiatry 2008, 69:213-221. (Pubitemid 351469264)
30. Kratochvil CJ, Newcorn JH, Arnold LE, et al.: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 2005, 44:915-924. (Pubitemid 41193203)
31. Wilens TE, Adler LA, Weiss MD, et al.: Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008, 96:145-154.
32. Biederman J, Monuteaux M, Spencer T, et al.: Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008, 165:597-603. (Pubitemid 351705336)
33. Nissen SE: ADHD drugs and cardiovascular risk. N Engl J Med 2006, 354:1445-1448.
34. Biederman J, Spencer TJ, Wilens TE, et al.: Treatment of ADHD with stimulant medications: response to Nissen Perspective in the New England Journal of Medicine. J Am Acad Child Adolesc Psychiatry 2006, 45:1147-1150. (Pubitemid 44465634)
35. Vetter VL, Elia J, Erickson C, et al.: Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008, 117:2407-2423. Important latest recommendations regarding cardiovascular safety of ADHD pharmacotherapy. (Pubitemid 351653546)
36. Vitiello B: Understanding the risk of using medications for ADHD with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am 2008, 17:459-474. This is a helpful summary on the cardiovascular safety of ADHD pharmacotherapy. (Pubitemid 351258356)
37. Gelperin K: Studying Cardiovascular Risk With Drug Treatments of ADHD. Rockville, MD: US Food and Drug Administration Drug Safety and Risk Management Advisory Committee; 2006.
38. Biederman J, Mick E, Surman C, et al.: Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry 2007, 7:49.
39. Neibler G, Wilens T, Weisler R, et al.: Evaluation of cardiovascular effects of lisdexamfetamine dimesylate treatment in adults with attention-deficit/hyperactivity disorder. Presented at the 2008 annual meeting of the American Psychiatric Association. Washington, DC; May 2008.
40. Berwaerts J, Orman C, Berry SA, et al.: Cardiovascular safety data from a long-term open-label study of OROS MPH in adults with ADHD. Presented at the 2008 annual meeting of the American Psychiatric Association. Washington, DC; May 2008.